Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.
Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 85–96 of 202 trials
Not yet recruitingNot specified
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System (opens on ClinicalTrials.gov)
This study is evaluating a new method for administering daratumumab, a treatment commonly used in the management of multiple myeloma and amyloidosis. For several…
- Study
- Interventional (treatment)
- Sponsor
- Hospices Civils de Lyon
Recruiting in: France
NCT07721350Updated 23 July 2026
Enrolling by invitationNot specified
AI Echocardiographic Screening of Cardiac Amyloidosis (opens on ClinicalTrials.gov)
Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and accurately…
- Study
- Interventional (treatment)
- Sponsor
- Cedars-Sinai Medical Center
Recruiting in: United States
NCT06664866Updated 22 July 2026
RecruitingNot specified
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening) (opens on ClinicalTrials.gov)
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a…
- Study
- Observational (registry, imaging)
- Sponsor
- Cedars-Sinai Medical Center
Recruiting in: United States
NCT05139797Updated 22 July 2026
RecruitingNot specified
[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy (opens on ClinicalTrials.gov)
The primary goal of this pilot study is to determine whether [64Cu]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Brigham and Women's Hospital
Recruiting in: United States
NCT07560306Updated 21 July 2026
Enrolling by invitationNot specified
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome (opens on ClinicalTrials.gov)
This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- University of Tennessee Graduate School of Medicine
Recruiting in: United States
NCT06907849Updated 21 July 2026
RecruitingNot specified
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study (opens on ClinicalTrials.gov)
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of…
- Study
- Interventional (treatment)
- Sponsor
- Wake Forest University Health Sciences
Recruiting in: United States
NCT06096675Updated 21 July 2026
RecruitingAL (light chain)
The Norwegian Immunotherapy in Multiple Myeloma Study (opens on ClinicalTrials.gov)
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in…
- Study
- Observational (registry, imaging)
- Sponsor
- St. Olavs Hospital
Recruiting in: Norway
NCT06855121Updated 20 July 2026
Not yet recruitingAL (light chain)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis (opens on ClinicalTrials.gov)
The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Nexcella Inc.
No study locations listed yet
NCT07709715Updated 16 July 2026
RecruitingAL (light chain)
Teclistamab-Daratumumab in AL Amyloidosis (opens on ClinicalTrials.gov)
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Rajshekhar Chakraborty, MD
Recruiting in: United States
NCT07110844Updated 13 July 2026
RecruitingATTR (transthyretin)AL (light chain)
Hungarian National Systemic Amyloidosis Registry (opens on ClinicalTrials.gov)
This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in…
- Study
- Observational (registry, imaging)
- Sponsor
- Semmelweis University
Recruiting in: Hungary
NCT07689331Updated 8 July 2026
RecruitingAL (light chain)
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) (opens on ClinicalTrials.gov)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close…
- Study
- Interventional (treatment)
- Sponsor
- Jin Lu, MD
Recruiting in: China
NCT06192979Updated 7 July 2026
RecruitingAL (light chain)
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (opens on ClinicalTrials.gov)
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Alexion Pharmaceuticals, Inc.
Recruiting in: CanadaUnited KingdomUnited States
NCT07081646Updated 2 July 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 7 November 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.